基本信息
浏览量:46
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Over more than two decades of research, Dr. Joyce’s area of focus has been in neuropharmacology, relating receptor pharmacology to the organization of transmitter systems in the brain and dysfunction. There have been three fundamental lines of research during his career. First, organization of monoaminergic and related neurotransmitter systems in the human brain and their alterations in schizophrenia. Second, the organization of dopamine (DA) receptors in the mammalian brain; particularly one subtype, the D3 DA receptor, its regulation and role in therapeutic response in schizophrenia. After 1995 this research theme was continued but focused on the role of D3 receptor preferring agonists to provide symptomatic relief in Parkinson’s disease and neuroprotection against loss of DA fibers and cell bodies. Between 1986 and 1995, the research from Dr. Joyce’s laboratories demonstrated that drug effects of antipsychotics could be dissected from disease processes. His work had major impact on the field of mental health and the biological substrates of schizophrenia and was awarded the prestigious Ziskind-Somerfeld Research Award for research into the biological substrates of schizophrenia by the Society for Biological Psychiatry in 1997. Another significant area of research was on drug targets for schizophrenia, and evidence that the DA D3 receptor was a key target for drug development, as changes in its regulation or expression were part of the “disease process” occurring with schizophrenia. That research has led to new drug development and was identified as a key contributor to policy change in mental health by Rand Corporation (Mental Health Retrosight, 2013, http://www.rand.org/pubs/research_briefs/RB9738.html).
From 1995 onward the focus for his research was in drug targets for improvement of Parkinson’s disease. In addition to establishing consortia to support translational research in Parkinson’s, his group established novel cell lines for study of dopaminergic cell death and neuroprotection and collaborated on novel rodent parkinsonian models. His longstanding interest in aging, neurodegenerative diseases and the role of the pre- and postsynaptic components of the DA system helped set the stage for his contributions to a better understanding of the clinical symptomatology in Parkinson’s and loss of response to antiparkinsonian therapeutics. That research has contributed to the continued interest in developing D3 receptor preferring agonists for treatment of Parkinson’s disease. Concurrent lines of research in his laboratory developed evidence that the D3 receptor also functioned to provide neuroprotection and/or neurorestoration of the presynaptic DA system with treatment with DA agonists. That work contributed to the continued interest in the importance of developing novel antiparkinsonian drugs that can produce neurorestoration as well as neuroprotection against the neurodegeneration of the DA system in Parkinson’s disease.
From 1995 onward the focus for his research was in drug targets for improvement of Parkinson’s disease. In addition to establishing consortia to support translational research in Parkinson’s, his group established novel cell lines for study of dopaminergic cell death and neuroprotection and collaborated on novel rodent parkinsonian models. His longstanding interest in aging, neurodegenerative diseases and the role of the pre- and postsynaptic components of the DA system helped set the stage for his contributions to a better understanding of the clinical symptomatology in Parkinson’s and loss of response to antiparkinsonian therapeutics. That research has contributed to the continued interest in developing D3 receptor preferring agonists for treatment of Parkinson’s disease. Concurrent lines of research in his laboratory developed evidence that the D3 receptor also functioned to provide neuroprotection and/or neurorestoration of the presynaptic DA system with treatment with DA agonists. That work contributed to the continued interest in the importance of developing novel antiparkinsonian drugs that can produce neurorestoration as well as neuroprotection against the neurodegeneration of the DA system in Parkinson’s disease.
研究兴趣
论文共 150 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Lesions and Transplantation (2013): 456
引用0浏览0引用
0
0
Julian Ball, M Fanthorpe, M Brindle, D Irving, C Jordon, M Kiddlemorris, Joel C W Rogers, H Stephens, C Walters, D Balckburn,Jeffrey N Joyce, Jackie Bracey,
mag(2010)
引用23浏览0引用
23
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn